Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Glioma Cells Achieve Malignant Progression by Fusion with Macrophages to Gain High SLC7A5 Expression

View through CrossRef
Abstract Background Glioma is the most prevalent primary tumor of the central nervous system (CNS) in adults, and its high proliferative and invasive capacities are typically associated with a poor prognosis. Cell fusions are a crucial phenomenon in both physiological and pathological processes. Within tumors, tumor cells can acquire diverse gene expression profiles and undergo malignant progression through fusion events with themselves or other somatic cells. This process leads to the emergence of stem cell characteristics, drug resistance properties, immune evasion abilities, and enhanced migration and invasion capacities. Macrophages (MФs) represent the predominant cell type within glioma immune microenvironments and are important partners for fusion events with glioma cells. However, the biological characteristics and underlying mechanisms of MФ-glioma fusion hybrids remain incompletely elucidated. Results We validated the presence of MФ-glioma double positive cells through analysis of glioma single-cell RNA sequencing (scRNA-seq) data and examination of glioma specimens. We successfully established the MФ-glioma cell fusion hybrid models in vitro. Subsequent propidium iodide (PI) staining combined with flow cytometry analysis revealed a significant increase in the chromosome content of hybrid cells. Research on the biological characteristics of MФ-glioma fusion hybrids has revealed their heightened proliferation and invasion capabilities. Further mechanistic investigations have elucidated that SLC7A5, a tumor-associated gene originating from parental MФs, orchestrates the augmented proliferative and invasive capabilities of hybrid cells via activation of the mTOR-RPS6 signaling pathway. Furthermore, the MФ-glioma fusion hybrids exhibited heightened sensitivity to a specific inhibitor of SLC7A5 (JPH203) compared to their parental cells. Conclusion Glioma cells achieve malignant progression by acquiring high expression of the tumor-associated gene SLC7A5 through fusion with MФs. This discovery provides a new perspective on the malignant biology of gliomas.
Title: Glioma Cells Achieve Malignant Progression by Fusion with Macrophages to Gain High SLC7A5 Expression
Description:
Abstract Background Glioma is the most prevalent primary tumor of the central nervous system (CNS) in adults, and its high proliferative and invasive capacities are typically associated with a poor prognosis.
Cell fusions are a crucial phenomenon in both physiological and pathological processes.
Within tumors, tumor cells can acquire diverse gene expression profiles and undergo malignant progression through fusion events with themselves or other somatic cells.
This process leads to the emergence of stem cell characteristics, drug resistance properties, immune evasion abilities, and enhanced migration and invasion capacities.
Macrophages (MФs) represent the predominant cell type within glioma immune microenvironments and are important partners for fusion events with glioma cells.
However, the biological characteristics and underlying mechanisms of MФ-glioma fusion hybrids remain incompletely elucidated.
Results We validated the presence of MФ-glioma double positive cells through analysis of glioma single-cell RNA sequencing (scRNA-seq) data and examination of glioma specimens.
We successfully established the MФ-glioma cell fusion hybrid models in vitro.
Subsequent propidium iodide (PI) staining combined with flow cytometry analysis revealed a significant increase in the chromosome content of hybrid cells.
Research on the biological characteristics of MФ-glioma fusion hybrids has revealed their heightened proliferation and invasion capabilities.
Further mechanistic investigations have elucidated that SLC7A5, a tumor-associated gene originating from parental MФs, orchestrates the augmented proliferative and invasive capabilities of hybrid cells via activation of the mTOR-RPS6 signaling pathway.
Furthermore, the MФ-glioma fusion hybrids exhibited heightened sensitivity to a specific inhibitor of SLC7A5 (JPH203) compared to their parental cells.
Conclusion Glioma cells achieve malignant progression by acquiring high expression of the tumor-associated gene SLC7A5 through fusion with MФs.
This discovery provides a new perspective on the malignant biology of gliomas.

Related Results

Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Abstract Introduction Due to indeterminate cytology, Bethesda III is the most controversial category within the Bethesda System for Reporting Thyroid Cytopathology. This study exam...
The Nuclear Fusion Award
The Nuclear Fusion Award
The Nuclear Fusion Award ceremony for 2009 and 2010 award winners was held during the 23rd IAEA Fusion Energy Conference in Daejeon. This time, both 2009 and 2010 award winners w...
Abstract 1809: Marizomib (NPI-0052) activity as a single agent in malignant glioma
Abstract 1809: Marizomib (NPI-0052) activity as a single agent in malignant glioma
Abstract Background: Glioblastoma multiforme (GBM) is a highly aggressive brain tumor, which displays innate resistance to multiple treatment modalities. Previous st...
PLEKHA4 is a prognostic biomarker and correlated with immune infiltrates in glioma
PLEKHA4 is a prognostic biomarker and correlated with immune infiltrates in glioma
Abstract Background Gliomas are the most common and life-threatening intracranial tumors. Immune-infiltration of the tumor microenvironment significantly affects tumor pro...
Rôle des facteurs de transcription NOR1 et TLE1 dans les macrophages alternatifs humains
Rôle des facteurs de transcription NOR1 et TLE1 dans les macrophages alternatifs humains
L’athérosclérose est une maladie inflammatoire chronique de la paroi vasculaire à évolution lente et silencieuse dont les principaux facteurs de risque sont les dyslipidémies, l’ob...

Back to Top